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Abstract
Background: Clinical signs are a fundamental aspect of human pathologies. While disease diagnosis is problematic
or impossible in many cases, signs are easier to perceive and categorize. Clinical signs are increasingly used, together
with molecular networks, to prioritize detected variants in clinical genomics pipelines, even if the patient is still
undiagnosed. Here we analyze the ability of these network-based methods to predict genes that underlie clinical signs
from the human interactome.
Results: Our analysis reveals that these approaches can locate genes associated with clinical signs with
variable performance that depends on the sign and associated disease. We analyzed several clinical and
biological factors that explain these variable results, including number of genes involved (mono- vs. oligogenic diseases),
mode of inheritance, type of clinical sign and gene product function.
Conclusions: Our results indicate that the characteristics of the clinical signs and their related diseases should
be considered for interpreting the results of network-prediction methods, such as those aimed at discovering
disease-related genes and variants. These results are important due the increasing use of clinical signs as an
alternative to diseases for studying the molecular basis of human pathologies.
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Background
Clinical signs are manifestations of a patient’s underlying
disease. While diseases are in many cases difficult or
even impossible to diagnose, clinical signs are easier to
recognize and in some cases, to quantify. It has recently
been shown that clinical signs have a reflection at the
molecular level; for example, their associated genes form
modules in the interactome, at least to the same extent
as diseases do [1]. All these factors make clinical signs a
valid partition of the human pathological landscape,
complementary to that based on diseases, which is re-
ceiving increasing attention.
In the study of the genetic basis of a disease, experimen-
tal validation of causal candidate genes is a time-
consuming and expensive process. To save resources
and maximize success, candidate genes obtained by
genetic/genomic approaches can be prioritized with
computational methods that consider a variety of previ-
ous information [2]. Among these, clinical signs of
known genetic diseases can be compared to those man-
ifested by a patient and be used to further prioritize
variants obtained from whole exome analysis [3]. The
obvious advantage of using patient’s clinical signs is
that prioritization can be performed even if the patient
has not yet been diagnosed or if his/her pathology is
unknown. Some of these clinical genomics approaches,
in addition to seeking whether a variant is already annotated
with similar manifestations in human and other model or-
ganism databases, also examine molecular networks to
prioritize variants following the guilt-by-association principle
[4–6], as genes that cause the same or similar diseases are
often found in close proximity in biological networks [7, 8].
Network-based methods used to prioritize candidate
genes require an initial set of genes, referred to as ‘seed’
[9], typically comprised by those previously known to
cause the diagnosed disease or causing diseases with
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similar clinical signs. Methods based on global distances,
such as random-walk with restart (RWR) [10, 11], have
been shown to outperform those based on local dis-
tances [12]. Several modifications of the RWR method
have also been proposed to account for disease pheno-
typic similarities [13, 14]. The fact that disease genes
map to relatively compact but not highly dense regions in
the network of protein-protein interactions (interactome)
have led to formulation of an alternative approach,
Disease Module Detection (DIAMOnD) [15], which
measures the connectivity significance of the candidates
relative to known disease genes, instead of their distance.
In a clinical setting (Fig. 1a) candidate variants are first
obtained by genetic analysis. Then all patient signs are
combined to find known diseases with similar manifesta-
tions. The genes causing these similar diseases are then
matched to the candidate variants. If no match is found,
candidates can be prioritized using the interactome,
using as seed those genes previously found to cause
similar diseases. Thus the ability to successfully prioritize
causal variants from both molecular networks and patient
clinical signs depends, among other factors, on the ability
of network methods to predict genes associated with these
signs. Known gene associations to a sign have been used
to predict novel genes associated to that particular sign
using molecular networks [16]. We recently analyzed the
network context of genes associated with clinical signs
in the human interactome and observed that, as in the
case of diseases, they generally form localized modules
[1]. We nonetheless observed that the compactness of
clinical signs varied notably, which is expected to affect
prediction performance for different clinical signs.
In this study (Fig. 1b) we assessed the ability of network-
based methods to predict genes associated with individual
clinical signs. We compared two methods previously used
to predict disease-gene relationships that follow two dis-
tinct approaches, random-walk with restart (RWR) [10, 11],
based on global distances, and DIAMOnD [15], based on
connectivity significance. While a conceptually similar
approach to RWR, PRINCE [11], was previously used
to predict sign-gene relationships [16], the ability of
DIAMOnD to predict novel sign-genes has not been pre-
viously reported. We provide a detailed analysis of several
clinical and biological factors that affect prediction per-
formance. Our results point to several factors that should
be taken into account when assessing the results provided
by network-based approaches that use clinical signs and
interactome data for gene prioritization, a practice in in-
creasing use.
Results
An overview of the analysis performed is summarized in
Fig. 2.
Evaluation of network methods
To compare the performance of RWR and DIAMOnD,
we tested 23,458 gene-clinical signs pairs from the OMIM
and HPO databases, corresponding to 522 unique non-
redundant signs and 2279 distinct genes (see Methods for
details). In order to recreate a ‘de novo’ prediction
Fig. 1 Comparison of a typical clinical setting and this study. a In a clinical setting patient’s clinical signs are combined to find similar known diseases
and define seed genes. b In this study, genes associated to individual signs are predicted using a leave-one-out approach
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scenario, for each prediction we removed one gene-
clinical sign association (the one to be predicted) and used
the remaining genes associated with the clinical sign as
seed. As an example to illustrate our results we selected
the clinical sign ‘Ketosis’, the presence of elevated levels of
ketone bodies in the body, as defined in HPO. We found
29 diseases annotated with this sign in OMIM. Of these,
23 had at least one causal gene, providing a total of 28
genes associated with ‘Ketosis’. Three of these genes were
not found in the interactome, thus leaving 25 genes for
testing (from 19 distinct diseases). We then performed 25
predictions, one for each of these 25 genes, using the
remaining 24 as seed. For each prediction we recorded the
rank of the left-out gene among the remaining nodes in
the interactome. Individual gene performances (using
RWR) for this sign varied from best prediction (rank = 1)
for IVD (isovaleryl-CoA dehydrogenase) causing isovaleric
acidemia, to worst (rank = 7525) for GK (glycerol kinase)
causing glycerol kinase deficiency. Overall RWR prediction
performance for ‘Ketosis’, measured as the Area Under the
ROC curve (AUC) of the 25 predictions, was 0.93.
We found that RWR outperformed DIAMOnD on the
1–1000 rank range (corresponding to up to 1000 itera-
tions of DIAMOnD) (Fig. 3). RWR predicted 35.85% of
the genes among the top 1000, in contrast to 20.18% by
DIAMOnD. Nonetheless, when we assessed perform-
ance for individual clinical signs (see Additional file 1:
Table S1), DIAMOnD was able to capture more true
positives in the top-ranking positions for a number of
them. For example, within the top 100 (corresponding to
a false positive rate (FPR) of 0.75%), DIAMOnD ob-
tained better results than RWR for 60 of the 522 clinical
signs. This number decreased at lower ranks, with 35 at
rank = 500 (FPR = 3.75%) and 26 at rank = 1000
(FPR = 7.5%).
We observed high variability in the results for individual
clinical signs for both RWR and DIAMOnD (see Fig. 4 for
RWR results). Among the best RWR results in the top
100, we found ‘Cerebral edema’ with 85% of its 27 genes
predicted, followed by ‘Lethargy’ (61%) and ‘Abnormality
of the coagulation cascade’ (59%). In contrast, RWR was
not able to predict any gene in the 100 top positions for
60 clinical signs. The best DIAMOnD results in the
Fig. 2 Overview of the data, methods and factors analyzed

















Fig. 3 Performance of RWR and DIAMOnD methods. Performance is
represented as percentage of true positives predicted among the
top ranking genes (from rank 1 to 1000)
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top100 were ‘Cerebral edema’ (52%), ‘Abnormal CSF
lactate level’ (51%) and ‘Plantar hyperkeratosis’ (41%).
DIAMOnD did not correctly predict any gene in the top
100 for 109 clinical signs. As RWR performed better overall
than DIAMOnD, we used RWR for subsequent analyses.
Analysis of clinical and biological factors that affect
performance
Given the nature of the RWR algorithm, its performance
depends on the compactness of each clinical sign in the
interactome, which is variable [1]. The percentage of
genes at distance 1 to another gene within the clinical
sign in OMIM varies from 85% (cerebral edema) to 0%
for 22 clinical signs, with an average value of 30% for all
signs analyzed. As expected, there was a correlation be-
tween RWR performance and clinical sign compactness
(not shown). We also evaluated the RWR prediction of
500 random sets (within variable random sizes in the 25–
75 range) obtaining a performance very close to random
prediction (AUC = 0.49).
The variability in compactness of clinical signs, and
therefore prediction performance, can be explained by
several clinical and biological factors. In this section we
present a detailed analysis of some of these factors, in-
cluding characteristics of the interactome, clinical sign
type and frequency, monogenic/oligogenic nature of
the associated disease, mode of inheritance and gene
function.
Compactness of biological processes in the interactome
Clinical signs can result from disruption of the same or
different biological processes. As an upper bound of per-
formance, we assessed the ability of RWR to predict
genes involved in different molecular, cellular and organ-
ismal processes. We analyzed 1118 biological processes
(distinct, non-redundant) from Gene Ontology.
We obtained better global performance for biological
processes (AUC = 0.83) than for clinical signs (AUC = 0.70).
In addition, RWR performance varied depending on the
process, from best results for ‘DNA replication-dependent
nucleosome organization’ (AUC = 1.0) to poorest for
‘cofactor transport’ (AUC = 0.42) (see Supplementary
Additional file 2: Table S2).
Analysis of results per general classes of processes re-
vealed that signaling and metabolic processes were among
the best predicted, whereas growth, reproduction and de-
velopmental processes were among the poorest (Table 1).
Given these results, we anticipated poorer performance
for those clinical signs related, for example, to devel-
opmental processes than those related to metabolic
processes. This later is the case of our illustrative sign
‘Ketosis’, a metabolic manifestation associated with sev-
eral diseases, which achieved one of the best perfor-
mances among the 522 signs analyzed (Supplementary
Additional file 1: Table S1). As expected, prediction
performance for multicellular organismal processes
(AUC = 0.78) was lower than for cellular processes
(AUC = 0.86).
Fig. 4 Variability in RWR performance for individual clinical signs. The 522 signs (small circles) are grouped into 18 general classes. Signs are
colored by AUC value (darker for better performance). Circle size is proportional to number of genes
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Monogenic vs. oligogenic diseases
In the case of oligogenic diseases, we can use their known
genes to predict others. When predicting genes associated
with monogenic diseases no other disease genes are
known and, as in the case of undiagnosed patients, indir-
ect strategies are needed to build the starting set of genes
(seed). One of these strategies, used in some genomic
pipelines [4–6], is to build a seed with genes of diseases
with similar clinical manifestations. Clinical signs might
thus seem most valuable in the discovery of variants
underlying monogenic diseases or generally in those cases
where a patient is still undiagnosed or his/her disease is
unknown.
In this work, we defined a disease as a distinct OMIM
phenotypic code, and classified them as mono- or oligo-
genic based on the number of associated genes in the
OMIM database that could be mapped in the interac-
tome (1 for monogenic, >1 for oligogenic; individual
OMIM phenotypes in phenotypic series were not treated
as oligogenic disease). For example, among the 19 diseases
with ‘Ketosis’ as clinical sign, two of them were classified
as oligogenic: maple syrup urine disease with 3 genes
(BCKDHA, BCKDHB and DBT) and Permanent neonatal
diabetes mellitus with 4 genes (GCK, INS, KCNJ11 and
ABCC8). The remaining 17 diseases were classified as
monogenic.
In this section we analyzed separately those ranks
obtained for genes associated with oligogenic diseases
(including 7 genes for ‘Ketosis’) and those for monogenic
diseases (including 17 genes for ‘Ketosis’). In terms of
gene-sign pairs, 19,973 corresponded to monogenic and
3894 to oligogenic diseases (409 pairs are from both
mono- and oligogenic diseases), for a total of 3060
monogenic and 170 oligogenic diseases. Note that when
predicting genes for a sign of a monogenic disease, seed
genes come necessarily only from other diseases with
that specific sign. In contrast, when predicting a gene
for a sign associated with an oligogenic disease, seed genes
contain genes from other diseases as well as other genes
affecting that particular disease.
The performance of RWR in predicting genes associated
with clinical signs of oligogenic diseases (AUC = 0.84) was
notably better than for those of monogenic diseases
(AUC = 0.68). As (i) these results might affect the analysis
of other factors, (ii) monogenic diseases are more nu-
merous in our dataset than oligogenic diseases, and (iii)
it is possible to directly predict genes associated with
oligogenic diseases using other known genes as seed,
we analyzed other factors affecting performance only
for monogenic diseases. In the ‘Ketosis’ example, 7 out
of 25 genes came from oligogenic diseases, thus only
the ranks of the remaining 17 were considered in the
following sections.
The alternative direct prediction of genes for oligogenic
diseases with RWR (e.g. predicting DBT gene as associated
to maple syrup urine disease using only BCKDHA and
BCKDHB genes as seed) yielded an AUC of 0.85. This is
only slightly better than the overall prediction obtained
through clinical signs (AUC = 0.84). To test whether par-
ticular clinical signs could improve the ranking obtained
by direct predictions of genes for oligogenic diseases, we
extracted the best rank for each gene from among all signs
for each disease. If we knew the best clinical sign for each
gene beforehand (not known a priori), this would give us
an upper bound of AUC = 0.91.
Clinical sign frequency
Some clinical signs are frequent manifestations of certain
diseases, whereas others appear less frequently. It is reason-
able to expect that those genes causing diseases for which
the sign is less frequent (low prevalence) are predicted
more poorly than those for which the sign is very frequent
(high prevalence). We therefore compared the performance
of gene-signs predictions for monogenic diseases compiled
in Orphanet, for which sign frequency data is available. In
this resource, signs are classified as ‘hallmark’, ‘typical’ and
‘occasional’ on a decreasing scale of prevalence.
As expected, hallmark signs had slightly better overall per-
formance (AUC = 0.70) than typical (AUC = 0.69) and occa-
sional signs (0.68), although differences are only marginal.
Mode of inheritance
Genes associated with autosomal dominant diseases are
found mainly as hubs or bottlenecks in the interactome,
Table 1 RWR performance for gene-process prediction, accord-
ing to general GO class
GO class N° proc. AUC(%)
signaling 69 89.50
metabolic process 196 88.27
response to stimulus 177 85.66
cellular process 461 85.58
immune system process 46 85.54
cellular component organization or biogenesis 100 85.18
biological regulation 519 82.79
single-organism process 518 82.65
multi-organism process 22 82.37
locomotion 14 82.12
localization 89 82.05
biological adhesion 8 80.76
multicellular organismal process 190 77.68
reproductive process 14 77.58
developmental process 172 77.03
reproduction 10 76.13
growth 5 72.85
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whereas those associated with autosomal recessive dis-
eases are frequently located at the periphery [17]. The
inheritance pattern of the disease(s) associated with a
given clinical sign is thus expected to affect the ability of
network-based methods to predict genes associated with
it. In this section we analyzed separately the ranks of
gene-sign predictions corresponding to ‘autosomal dom-
inant’ and ‘autosomal recessive’ diseases. Indeed, RWR
rendered a prediction performance of AUC = 0.78 for
the 8116 gene-sign pairs associated with monogenic dis-
eases annotated as ‘autosomal dominant’, and a much
lower value for the 12,558 gene-sign pairs of ‘autosomal
recessive’ monogenic diseases (AUC = 0.63).
In the example case, ‘Ketosis’, 14 of the 17 monogenic
diseases were annotated as ‘autosomal recessive inherit-
ance’, so the ranks of the 14 genes associated with these
diseases were analyzed as part of the autosomal recessive
group. Among the 17 ketosis-associated monogenic dis-
eases, no monogenic autosomal dominant diseases were
found, so this sign did not contribute to the analysis of
autosomal recessive diseases.
Clinical sign classes
The variability of results for different clinical signs is also
expected to be shown at broad sign classes. We analyzed
the ranks obtained by RWR (monogenic diseases only)
grouped by 18 classes of clinical signs, corresponding to
the most general HPO terms under ‘Phenotypic abnor-
mality’ (note that a given sign can belong to various
classes). Performance varied among clinical sign classes
(Table 2). The best results were obtained for ‘neoplasms’
and signs related to blood and blood-forming tissues.
Signs of the endocrine, cardiovascular, immune systems,
integument and metabolism/homeostasis classes had a
performance score of AUC > 0.7. RWR generally per-
formed more poorly for signs related to the eye, nervous
system, growth abnormalities and ear. Our ability to pre-
dict genes thus currently depends on the type of clinical
signs a patient manifests.
‘Ketosis’, our example sign, is classified according to
HPO as an ‘Abnormality of metabolism/homeostasis’. To
measure the overall performance this group of signs, we
analyzed all the ranks obtained for genes causing mono-
genic diseases (including the 17 genes associated with
‘Ketosis’), together with those genes associated with other
metabolism/homeostasis signs. The overall performance
of this general class of signs was AUC = 0.72.
Disease onset and pace of progression
Severity of manifestations in the organism can vary
within the interactome throughout life. We therefore an-
ticipated some differences at the interactome level be-
tween diseases that arise early in development and those
that appear later, as well as between those with slow
versus rapid progression, which in turn would affect the
performance of network-based methods for predicting
genes associated with clinical signs. We analyzed the
ranks of gene-sign predictions grouped by disease onset
according to six HPO annotations: congenital (at birth),
neonatal (first 28 days), infantile (28 days-1 year), child-
hood (1–5 years), juvenile (5–15 years) and adult
(>15 years). In general, prediction performance increases
from earlier to later age (Table 3), except for ‘juvenile’
and ‘neonatal’ onsets. In the Ketosis example, only two
diseases were associated with onset data: Methylmalonic
aciduria, cblA type (caused by MMAA) annotated as
both ‘neonatal’ and ‘infantile’ and Glycogen storage dis-
ease IXc (caused by PHKG2) which also an infantile dis-
ease according to HPO. Therefore the ranks obtained
for the Ketosis predictions of MMAA (rank = 15) and
PHKG2 (rank = 604) were used, among other signs, to
calculate the overall performance of infantile onset,
Table 2 RWR performance for gene-sign prediction, according
to general HPO classes
Clinical sign class N° pairs AUC (%)
Neoplasm 235 80.77
Abnormality of blood and blood-forming tissues 566 77.02
Abnormality of the endocrine system 307 74.56
Abnormality of the cardiovascular system 1027 73.84
Abnormality of the immune system 609 72.91
Abnormality of the integument 1155 72.68
Abnormality of metabolism/homeostasis 953 72.15
Abnormality of the musculature 895 69.47
Abnormality of the abdomen 1444 68.45
Abnormality of connective tissue 293 67.99
Abnormality of the skeletal system 3460 67.52
Abnormality of head and neck 4071 67.33
Abnormality of the respiratory system 406 67.17
Abnormality of the genitourinary system 1182 66.55
Abnormality of the ear 628 65.74
Growth abnormality 547 65.71
Abnormality of the nervous system 3995 64.70
Abnormality of the eye 1908 64.39
Table 3 RWR performance for gene-sign prediction, according
to disease onset
Onset N° pairs AUC(%)
Juvenile onset 993 75.08
Neonatal onset 203 74.93
Adult onset 1068 72.80
Infantile onset 2410 70.13
Childhood onset 341 69.03
Congenital onset 1518 65.32
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while only the Ketosis prediction for MMAA contrib-
uted (together with other sign results) to the perform-
ance of neonatal onset.
Similarly, predictions are better for signs associated
with non-progressive disorders (AUC 0.79) than for pro-
gressing pathologies (AUC 0.61) (see Table 4 for details).
Gene product function
Protein function can affect prediction performance in
two ways; 1) due to the way it was constructed, our inter-
actome might be enriched in certain functions to the det-
riment of others and, as shown above, 2) the interactome
compactness of different biological processes affects the
results as well. We analyzed the differences in perform-
ance for three aspects of protein function, molecular
activity (MF), biological processes (BP) and cellular
localization (CC) using its Gene Ontology annotations
(see Additional file 3: Table S3).
We evaluated the overall performance of a GO term
by calculating the AUC values from the ranks of those
gene-sign pairs whose genes were annotated with that
particular term. For example, 20 the 21 genes of mono-
genic diseases associated to ‘Ketosis’ (all except MMAA
gene) were annotated with ‘metabolic process’ term in
GO. So their corresponding ranks (obtained for Ketosis
prediction), as well as the ranks of all gene-sign pairs
corresponding to ‘metabolic process’ genes, were used to
calculate the overall ‘metabolic process’ performance
(AUC = 0.69).
Among the results with the highest performance for
molecular activities were ‘chemoattractant’, ‘proteasome
regulator’, ‘translation regulator’ and ‘antioxidant’, with
above average performance for ‘structural molecule’, ‘mo-
lecular transducer’ and ‘transcription regulator’, and below
average for unknown, ‘metallochaperone’, ‘transporter’ and
‘nutrient reservoir’. In the case of biological processes, we
observed better performances for ‘reproduction’, ‘cell kill-
ing’ and ‘biological adhesion’, below average performances
for unknown, ‘viral reproduction’, ‘immune system process’,
‘growth’ and ‘response to stimulus’. Finally, highest AUC
values for cellular localization were ‘chromosomal part’,
‘extracellular matrix’, ‘cytoplasmic vesicle’ and ‘nuclear part’,
whereas the lowest and below average values were for
‘mitochondrial membrane’, unknown, ‘endosomal part’,
‘endoplasmic reticulum’ and ‘cilium’.
Impact of factors on a clinical setting
In the previous sections, we analyzed the impact of sev-
eral clinical and biological factors on the network-based
prediction of genes associated to individual clinical signs.
In a clinical setting (Fig. 1a), however, network-based
methods consider simultaneously all of a patient’s clin-
ical manifestations, not each individual sign in isolation.
We anticipate that the factors analyzed for individual
signs in this study would also have an impact in this
use-case (disease-gene prediction).
To confirm this, we analyzed the impact of a subset of
factors on disease-gene prediction. For this analysis we
performed a leave-one-out prediction of gene-disease
pairs, instead of gene-sign pairs. For example, to predict
the association of IVD gene to isovaleric academia, a
monogenic disease according to OMIM, we first ob-
tained the disease’s signs (ketoacidosis, among others),
including also their ancestor terms in the HPO hier-
archy. We then searched for diseases manifesting at least
one of those clinical signs, and compiled their associated
genes. These genes (excluding IVD) were used as seed
for RWR prediction (see Methods for details on seed
weights). Seed genes in this case, are therefore obtained
from the combination of all clinical signs associated to a
disease.
Oligogenic diseases were better predicted than mono-
genic (as for individual signs). Analysis of monogenic
diseases showed that overall disease-gene prediction per-
formance (AUC 0.79) was higher than overall clinical
sign-gene prediction (AUC 0.68). Nevertheless, variability
and trends for each factor analyzed in the two scenarios
were generally similar (see Additional file 4: Table S4).
Discussion
Clinical signs associated with genetic diseases, together
with molecular networks, are being used increasingly in
clinical genomics pipelines to help prioritize genomic
variants [4–6]. Although clinical signs map to localized
areas in the currently known human interactome, their
compactness varies notably [1] and can thus have a dif-
ferent effect on gene prioritization performance.
Using 23,458 gene-clinical signs pairs compiled from
OMIM and HPO databases and the same human inter-
actome data analyzed in our aforementioned study of
compactness [1], we compared two network approaches
used previously for associating genes to diseases for their
capacity to predict associations between genes and signs.
These are based on global network distances (RWR) and
connectivity significance (DIAMOnD). RWR outperformed
DIAMOnD on overall prediction results. DIAMOnD was
nonetheless reported to perform better than RWR in lower
ranks in the analysis of synthetic modules [15]. Our results
suggest that global distances are generally more inform-
ative than connectivity significance when predicting genes
Table 4 RWR performance for gene-sign prediction according
to disease pace of progression
Pace of progression N° pairs AUC (%)
Nonprogressive disorder 219 78.68
Slow progression 1112 65.79
Progressive disorder 1657 61.24
Rapidly progressive 359 60.30
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associated with clinical signs. DIAMOnD nonetheless
provided better results than RWR at lower ranks for
some of the clinical signs tested. Connectivity significance
is therefore especially valuable when no direct interactions
are available.
Prediction performance varied for different clinical
signs. Similarly variable performance is also described for
predicting disease-associated genes [12]. We can explain
this by the different degree to which clinical signs are
reflected as compact modules in the interactome, which
in turn depends on a number of clinical and biological fac-
tors analyzed. All these factors are expected to have an
impact in the network-based prioritization of variants for
unknown diseases and undiagnosed patients, as they ac-
count for general trends observed in the analysis of
already known diseases.
Molecular networks reflect different functional modules
in the cell, such as molecular complexes and biological
processes [18]. The molecular network analyzed here
mainly represents direct physical interactions between pro-
teins, and a smaller set of other types of functional rela-
tions. We assessed the ability of RWR to recover genes
that participate in different biological processes. RWR was
able to predict genes associated with biological processes
with good performance. Performance nonetheless varied
from one process to another, with poorer results in general
for multicellular organismal processes than for cellular pro-
cesses. This is reasonable, as multi-cellular processes must
be orchestrated at higher levels that are probably beyond
protein interactions.
Genes associated with clinical signs of oligogenic dis-
eases can be prioritized using previously known disease-
genes as seeds. For oligogenic diseases, we observed simi-
lar performance by this direct disease-gene prediction as
that of overall sign-gene prediction. Direct disease-gene
prediction is not possible for monogenic diseases,
however, and alternative strategies must be used to
build a seed, like those based on diseases with similar
clinical signs [4–6]. We obtained notably better results
predicting gene-sign pairs for oligogenic than for
monogenic diseases. Our results suggest that genes
from oligogenic diseases are involved in closer molecu-
lar mechanisms than genes from distinct monogenic
diseases, even when they manifest the same clinical
sign. We analyzed other factors affecting performance
only for monogenic diseases as they recreating the case
of undiagnosed patients or those manifesting diseases
with unknown etiology.
Mode of inheritance is another important factor to
consider. Genes associated with signs of autosomal dom-
inant diseases (AD) were better predicted than those
corresponding to autosomal recessive diseases (AR). Our
observations agree with a previous study that observed
that AD disease-genes tend to be hubs or bottleneck
genes on the interactome, whereas AR disease-genes
were found mostly in the periphery [17].
Prediction performance was also variable for clinical
sign classes. RWR generally performed more poorly
for signs related to the eye, nervous system, growth
abnormalities and ear. Some of these were also
reflected in the analysis of biological processes. This
might be due to inherent differences in the network
topology of these processes, or to our still incomplete
interactome. If the latter is the case, our results high-
light relevant clinical manifestations that are currently
under-investigated at the molecular/network level, and
hence point to underexplored interactome regions that
merit further attention.
Gene function might affect interactome complete-
ness and explain variable performance. Genes with un-
known functions performed less well than genes with
known functions (in all types of functions), even if
functional annotations were not explicitly considered
during prediction. This can be explained by the inter-
actome analyzed, for which almost half of the interac-
tions are derived from “literature-curated” low-throughput
experiments, typically performed on well-studied proteins.
For a small percentage of these ‘unknown function’
genes, we were nonetheless able to predict a clinical
manifestation.
Genes acting as nutrient reservoirs, metallochaperones
and transporters were predicted below average. This
could be due not to direct, but to indirect links (through
nutrients, metal ions and substances transported) not
reflected in our interactome. Similar poorer-than-average
results were obtained for genes involved in processes
related to ‘viral reproduction’, ‘immune system process’,
‘growth’ and ‘response to stimulus’, again probably due
to systemic or environmental factors not reflected in
the interactome. Those genes located in the mitochon-
dria, endosomes, endoplasmic reticulum, Golgi appar-
atus and cilia were also generally poor performers. All
of these locations can affect the overall energy flow and
molecular content of the cell by mechanisms not in-
volving direct protein interactions. Genes involved in
reproduction were among the best for predicting their
association to clinical signs, but were among the poor-
est when predicting their association to their own pro-
cesses (‘reproductive process’, as defined in the Gene
Ontology).
Better predictions were obtained for signs associated
with diseases with early onset. This could be due to the
greater severity of these diseases, which could in turn be
related to more compact modules in the interactome. Fi-
nally, the frequency with which a clinical sign manifests
in a disease affected the prediction results only margin-
ally. In any case, frequency data are currently available
only for a subset of diseases. It would be of interest to
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collect and use this type of information and further con-
sider it in the analysis.
All of these factors would also affect network-based
disease-gene prediction approaches, in which the entire
spectrum of signs manifested in a patient are considered
simultaneously. Here we analyzed a number of such fac-
tors and observed a trend similar to the case of individ-
ual sign prediction.
Our current ability to predict genes associated with
clinical signs is quite variable, and is related to their top-
ology in the human interactome. This variable topology
can be explained by a partially incomplete interactome,
but can also reflect the different natures of the molecu-
lar mechanisms that underlie clinical signs. Prediction
performance will improve as our knowledge of the hu-
man interactome completes and as new associations be-
tween genes and clinical signs are compiled. Therefore, in
a clinical setting it will advantageous to integrate data
from multiple sources to collect the most updated and
complete human interactome and reference set of known
gene-sign associations. We nonetheless suspect that net-
work approaches such as RWR will never reveal the more
‘indirect’ functional linkages inherent to the nature of
some clinical signs, especially those involved in multicellu-
lar processes. A deeper analysis of these functional link-
ages will certainly help to develop novel strategies and
approaches, and therefore improvements on current pre-
diction performance.
Conclusions
Our results show that global network distance has
greater predictive value than connectivity significance
for prediction of genes associated with individual clin-
ical signs. Performance is extremely variable, and de-
pends essentially on the topology of the sign in the
molecular network, which is in turn affected by differ-
ent clinical and biological factors. In practical terms,
our recommendation is that the characteristics of clin-
ical signs and their related diseases be taken into ac-
count for interpreting the results of network-prediction
methods.
A partition of the human pathological landscape in
clinical signs has obvious advantages, since these are
easier to identify and classify than diseases. As a conse-
quence, signs are being used increasingly to study the
molecular basis of human pathologies. Our results
point to important factors that should be taken into ac-
count in such studies.
Methods
Data
Clinical sign-gene associations were compiled as in a
previous study [1]. Briefly, diseases and their clinical signs
and symptoms were downloaded from the Human
Phenotype Ontology (HPO) [19] and disease-gene associa-
tions were obtained for OMIM (Online Mendelian Inher-
itance in Man) [20], as provided by the HPO. As our
objective was to assess the impact of clinical and bio-
logical factors on collection of non-redundant dis-
eases we chose OMIM as a public and carefully
curated database of genetic diseases and HPO as the
source of human clinical manifestations that is used
in current genomic pipelines that integrate network
and clinical signs. Clinical sign-gene pairs were gen-
erated based on their associations with the same dis-
ease(s). These sign-gene associations were further
expanded to ancestor terms in the HPO hierarchy.
We then selected those terms with at least 25 genes
in the ‘Phenotypic abnormality’ sub-ontology, and
kept only the most specific terms among them ac-
cording to the HPO hierarchy for further analysis.
This resulted in 522 unique non-redundant signs. In
this way, we avoided redundancy, while a minimum size
of 25 genes allows the detection of meaningful modules
in the interactome analyzed [21].
Interactome data were obtained from the supplementary
data of [21]. These authors compiled an integrated human
interactome of 141,296 physical interactions among 13,460
proteins, comprising literature-curated interactions,
high-throughput physical interactions, protein complexes,
regulatory interactions, enzyme-coupled interactions,
kinase-substrate pairs and other signaling interactions. We
evaluated the performance of predictions only for those
genes associated with clinical signs available in the interac-
tome. The final test set comprised a total of 23,458 clinical
sign-gene pairs, corresponding to 522 distinct signs and
2279 distinct genes.
Data on mode of inheritance of diseases, their onset
and pace of progression was obtained from HPO. Preva-
lence data on clinical signs (their frequency in their
respective diseases) was obtained from Orphanet dis-
eases (Orphanet: an online rare disease and orphan
drug data base. © INSERM 1997. Available on
http://www.orpha.net). Frequency data of clinical signs
for each disease were transferred to the corresponding
sign-gene pair. Using the same approach described above
for OMIM diseases, we analyzed a final set of 436 non-
redundant specific clinical signs with at least 25 genes for
Orphanet diseases. Gene Ontology annotations were
downloaded from DAVID gene (Database for Annotation,
Visualization and Integrated Discovery) [22].
Prediction analysis
Using this set of clinical-sign-gene pairs we then per-
formed a leave-one-out cross-validation with both RWR
and DIAMOnD algorithms; for each clinical sign we re-
moved one gene at a time (gi), and made a prediction
for it using the remaining genes as seed, with equal
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probabilities. We then assessed the rank assigned to each
test gene (gi). The rank for DIAMOnD corresponds to
the iteration in which the test gene is added to the seed.
A rank of 1 would thus mean that the gene was found in
the first iteration of the method. For RWR, we obtained
a ranked list of genes, with all the nodes in the interac-
tome sorted by final score. The rank assigned to test
gene gi is the position in this sorted list, excluding the
seed genes. The gamma parameter for RWR was set to
0.4, since that value yielded the maximum overall per-
formance in our tests.
We used the MATLAB implementation of RWR dis-
tributed by [14]. The adjacency matrix constructed from
the human interactome was normalized as in PRINCE
(Prioritization and Complex Elucidation) [11]. We used
the DIAMOnD algorithm [15] available at https://
github.com/barabasilab/DIAMOnD.
For disease-gene prediction, we used the RWR method
only, performing a leave-one-out cross-validation. We se-
lected those OMIM diseases with at least one gene and
one phenotypic abnormality in HPO. For each disease-
gene pair, genes associated with all the HPO terms anno-
tated for the test disease and their parents in the ontology
(except the one to predict) were used as seeds. Initial
probability of each seed gene was set to max[1/(ni-1)],
where ni is the number of genes associated with term i,
for all its associated HPO terms.
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